c met inhibitor su11274 Search Results


hgf receptor c-met inhibitor pha665752  (Biomol GmbH)
90
Biomol GmbH hgf receptor c-met inhibitor pha665752
Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor <t>PHA665752</t> ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM
Hgf Receptor C Met Inhibitor Pha665752, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+met+inhibitor+su11274/pmc07724458-89-56-62?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
hgf receptor c-met inhibitor pha665752 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
c-met inhibitor, su11274  (FUJIFILM)
90
FUJIFILM c-met inhibitor, su11274
Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor <t>PHA665752</t> ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM
C Met Inhibitor, Su11274, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+met+inhibitor+su11274/pmc04179721-93-8-9?v=FUJIFILM
Average 90 stars, based on 1 article reviews
c-met inhibitor, su11274 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
c met inhibitor su11274  (Pfizer Inc)
86
Pfizer Inc c met inhibitor su11274
Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor <t>PHA665752</t> ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM
C Met Inhibitor Su11274, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+met+inhibitor+su11274/10__1080_slash_2162402x__2016__1219828-119-9-12?v=Pfizer+Inc
Average 86 stars, based on 1 article reviews
c met inhibitor su11274 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor PHA665752 ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM

Journal: Stem Cell Research & Therapy

Article Title: Paracrine stimulation of perinatal lung functional and structural maturation by mesenchymal stem cells

doi: 10.1186/s13287-020-02028-4

Figure Lengend Snippet: Growth factors were not responsible for the stimulating effect of MSC-CM on Na + transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as boxes and whiskers with the 10–90 percentiles, mean (+), and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. a Inhibition of VEGF-R with Axitinib ( n = 19–23, 2 IE; *** p < 0.001), b BMP-R with K02288 ( n = 22–24, 2 IE; *** p < 0.001), and c PDGF-R with AG-1296 ( n = 18–22, 2 IE; *** p < 0.001) did not affect Na + transport in MSC-CM-treated and control cells. d The EGF-R inhibitor AG-1478 ( n = 19–24, 2 IE; *** p < 0.001), e the TGF-β-R inhibitor SB431542 ( n = 21–24, 2 IE; * p < 0.05; *** p < 0.001), f the FGF-R inhibitor FIIN-2 ( n = 16–24, 2 IE; * p < 0.05; ** p < 0.01; *** p < 0.001), and g the HGF-R (c-met) inhibitor PHA665752 ( n = 64–67, 6 IE; ** p < 0.01; *** p < 0.001) reduced ∆ I amil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. □ control, ■ MSC-CM

Article Snippet: The inhibitors of the VEGF receptor (Axitinib, 10 μM), the bone morphogenetic protein receptor (BMP-R; K02288, 1 μM), the platelet-derived growth factor receptor (PDGF-R; AG-1296, 10 μM), the EGF receptor (EGF-R; AG-1478, 1 μM), the transforming growth factor β receptor (TGF-β-R; SB431542, 1 μM), the FGF receptor (FGF-R; FIIN-2, 1 μM), and the HGF receptor c-met (PHA665752, 1 μM) were purchased from Biomol (Hamburg, Germany).

Techniques: Control, Inhibition